To Market Or Not To Market? Roche Fights Amgen Patent Litigation
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While FDA's review of the Mircera BLA offers a focal point for the agency's battle to keep ESA labeling abreast of ESA science, the Mircera molecule itself may not see the U.S. market.